Skip Navigation Links  
 

What is the Discover Study?

The Discover Study is a randomized, double-blind, placebo controlled study. “Randomized” means that it will be determined by chance which of the treatment groups you will be assigned to. “Double-blind” means that neither the participant nor the research team will know whether a participant is taking the placebo or the investigational drug. Participants will be treated with a low, middle, or high dose of Posiphen, or a placebo (a capsule that looks like the study drug but does not contain active ingredients).

In the Discover study, scientists will test the viability of posiphen, an investigational medication that may delay Alzheimer’s disease (AD) onset and slow the progression of the disease.

Discover is a Phase 1b study. It means that participants will help to determine the side effects of the drug and how the drug is metabolized by the human body (pharmacokinetics). The primary outcome measures of this study are safety and tolerability, pharmacokinetics measured on serum and cerebrospinal fluid, and the dose effect on the production rate of Beta Amyloid 40.

What is Posiphen?

Posiphen is an experimental drug developed as a selective inhibitor of amyloid precursor protein (APP) production. It was discovered by the US National Institute on Aging (NIA) and has the potential to delay Alzheimer’s disease (AD) onset and slow the progression of brain damage due to amyloid build-up.

Discover Study Sites

Discover will be actively launching recruitment at the following academic medical centers soon! If you are interested in learning more about the study, please contact Archana Balasubramanian at archana@ucsd.edu or (858)246-1277.

StateCitySiteContactTelephoneEmail
CALa JollaUniversity of California, San DiegoHelen Vanderswag(858)249-0556hvanderswag@ucsd.edu
INIndianapolisIndiana UniversityGena Antonopoulos(317)963-7428ganto@iu.edu
MOSt. LouisWashington University, St. Louis   

Questions? Please contact Archana Balasubramanian at archana@ucsd.edu or (858) 246-1277.